Amgen looks to jump-start academic research; Bayer eyes animal health deals;

@FierceBiotech: Buzz: Cellectis could be in a line for a $1.6B Pfizer buyout. Article | Follow @FierceBiotech

@JohnCFierce: Is this a good time to tout my survey (with Bloomberg Intelligence)? Are biotech assets overvalued? Check it out | Follow @JohnCFierce

> Amgen ($AMGN) is offering up a catalog of research tools and reagents to academic institutions with the goal of jump-starting projects in biology, launching the Amgen Biology-Enabling Resource, or AmBER. News

> Bayer's impending move to spin off its plastics business is soon to give the drugmaker a large cash sum, and CEO Marijn Dekkers said the company may splurge to bolster its animal health division. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: Deerfield backs startup with $10M for its hemodialysis vascular access implant. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ info from the company: CareFusion's Avea ventilator recalled as potentially deadly. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific slapped with $100M verdict in vaginal mesh suit. News | Follow @EmilyWFierce

> Zimmer ($ZMH) to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close. More

> Nonprofit leads $17.5M round for medical image exchange startup LifeImage. Article

Pharma News

@FiercePharma: Tech makers market health wearables to dog owners. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Lundbeck's EU lobbying yields political boost for anti-alcohol med Selincro. Article | Follow @CarlyHFierce

> Bayer chief may plow spinoff cash into animal health buys. Article

> Betting on Pfizer ($PFE) merger--or CEO goodbye--traders go bullish on Glaxo ($GSK). Story